Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1

Conditions

Carcinoma, Non-Small-Cell Lung 7Lung Neoplasms 2Brain Neoplasms 2Thyroid Neoplasms 1Glioblastoma 1Central Nervous System Neoplasms 1Bone Neoplasms 1

Interventions

selpercatinib 2pembrolizumab 2130-nm albumin-bound paclitaxel 2vandetanib 1trametinib 1sapanisertib 1repotrectinib 1regorafenib 1pralsetinib 1methyl N-acetylsibirosaminide 1lenvatinib 1fludarabine 1cemiplimab 1alectinib 1aldesleukin 1Thyrotropin Alfa 1Presenilin-1 1Panitumumab 1Interleukin-15 1Imatinib Mesylate 1IT-101 1IFL protocol 1Gemcitabine 1Dacarbazine 1Cyclophosphamide 1Clinical Trials, Phase II as Topic 1Cetuximab 1Capecitabine 1Camptothecin 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Thyroid Neoplasms × alectinib × Clear all
NCT03131206 2021-09-27

A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer

Dana-Farber Cancer Institute

Phase 1/2 Terminated
5 enrolled 8 charts
Head & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡